Analyzing Curaleaf (CURLF) and The Competition

Curaleaf (OTCMKTS:CURLF) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its peers? We will compare Curaleaf to similar companies based on the strength of its analyst recommendations, risk, valuation, earnings, institutional ownership, profitability and dividends.

Profitability

This table compares Curaleaf and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curaleaf	-0.76%	0.43%	0.13%
Curaleaf Competitors	-278.16%	-150.10%	-21.89%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Curaleaf and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curaleaf	0	1	2	1	3.00
Curaleaf Competitors	4264	10506	18254	825	2.46

Curaleaf currently has a consensus target price of $6.00, indicating a potential downside of 37.50%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 16.57%. Given Curaleaf’s peers higher possible upside, analysts plainly believe Curaleaf has less favorable growth aspects than its peers.

Insider & Institutional Ownership

0.0% of Curaleaf shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Curaleaf and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Curaleaf	$1.27 billion	-$231.07 million	-73.85
Curaleaf Competitors	$1.89 billion	$138.79 million	11.32

Curaleaf’s peers have higher revenue and earnings than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Curaleaf has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Curaleaf’s peers have a beta of 2.57, suggesting that their average share price is 157% more volatile than the S&P 500.

Summary

Curaleaf peers beat Curaleaf on 8 of the 13 factors compared.

About Curaleaf

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.